Grail annual revenue
2022
2023
2024
2025
Grail Revenue Growth & History (GRAL)
Grail reported $147.2M in revenue for fiscal 2025, an increase of 17.18% from the previous fiscal year.
View full Grail company overviewGrail annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $147.2M | $21.6M | +17.18% |
| 2024 | 2024-12-31 | $125.6M | $32.5M | +34.90% |
| 2023 | 2023-12-31 | $93.1M | $37.6M | +67.61% |
| 2022 | 2023-01-01 | $55.5M | — | — |
Grail quarterly revenue
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $44.7M | $9.1M | +25.72% |
| Q1 2026 | 2026-03-31 | $40.8M | $8.9M | +28.11% |
| Q4 2025 | 2025-12-31 | $43.6M | $5.3M | +13.97% |
| Q3 2025 | 2025-09-30 | $36.2M | $7.5M | +26.32% |
| Q2 2025 | 2025-06-30 | $35.5M | $3.6M | +11.18% |
| Q1 2025 | 2025-03-31 | $31.8M | $5.1M | +19.15% |
| Q4 2024 | 2024-12-31 | $38.3M | — | — |
| Q3 2024 | 2024-09-30 | $28.7M | $7.9M | +38.27% |
| Q2 2024 | 2024-06-30 | $32.0M | $9.6M | +42.63% |
| Q1 2024 | 2024-03-31 | $26.7M | — | — |
| Q3 2023 | 2023-10-01 | $20.7M | — | — |
| Q2 2023 · Jun 30 | 2023-06-30 | $22.4M | — | — |
Grail revenue growth trends
Grail's latest reported quarter, Q2 2026, generated $44.7M in revenue, an increase of 25.72% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Grail source filings ↗Community posts
FDA advisers back GRAIL’s Galleri test; final decision remains pending
An FDA advisory committee voted in favor of the benefit-risk profile of GRAIL ($GRAL)’s Galleri multicancer early-detection test for adults aged 50 and older. The benefit-risk vote was seven to two, with one abstention. Panel members unanim ...
